insulin

As insulin-makers face long-standing complaints of price-gouging, California is diving into the prescription drug business, attempting to produce its own brand of generic insulin and sell it at below-market prices to people with diabetes.

A journalist with Type 1 diabetes describes unexpectedly battling prior authorization delays as his supply of insulin dwindled.

The price of insulin in the U.S. has more than doubled since 2012, putting the life-saving hormone out of reach for some people with diabetes.

Summary: On May 24, 2017, the Type 1 Diabetes Defense Foundation filed two new lawsuits in federal court with class-action law firm Keller Rohrback, L.L.P., seeking disclosure of manufacturers’ net realized prices on blood glucose test strips and emergency glucagon kits, both used in diabetes treatment. Following on T1DF’s insulin pricing lawsuit filed March 17, 2017 (Boss, et al. v. CVS, et al.), T1DF now joins with individual plaintiffs in test strip claim Prescott, et al. v. CVS, et al. and glucagon claim Bewley, et al. v. CVS, et al., expanding its consumer rights campaign against the unconscionable pricing of essential pharmaceuticals. These lawsuits are consistent with T1DF’s opposition to “rebates” and other hidden pricing practices that raise list prices for diabetes drugs and supplies while disincentivizing innovation, promoting clinical inertia, undermining therapeutic adherence and encouraging discrimination against people with diabetes.